65,113 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Bought by Trexquant Investment LP

Trexquant Investment LP bought a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 65,113 shares of the biotechnology company's stock, valued at approximately $3,281,000. Trexquant Investment LP owned 0.06% of Corcept Therapeutics at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Corcept Therapeutics by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 10,115,624 shares of the biotechnology company's stock worth $509,726,000 after acquiring an additional 109,294 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Corcept Therapeutics by 0.4% in the 4th quarter. Parallel Advisors LLC now owns 3,829,632 shares of the biotechnology company's stock worth $192,975,000 after purchasing an additional 15,908 shares in the last quarter. State Street Corp boosted its position in shares of Corcept Therapeutics by 0.6% in the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company's stock worth $162,871,000 after purchasing an additional 19,893 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Corcept Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,378,758 shares of the biotechnology company's stock worth $110,108,000 after buying an additional 99,470 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its position in Corcept Therapeutics by 4.1% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,644,942 shares of the biotechnology company's stock valued at $82,889,000 after buying an additional 64,321 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Sean Maduck sold 100,000 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $100.54, for a total transaction of $10,054,000.00. Following the completion of the sale, the insider now owns 85,622 shares in the company, valued at approximately $8,608,435.88. This represents a 53.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Joseph Douglas Lyon sold 421 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $60.58, for a total value of $25,504.18. Following the completion of the transaction, the insider now directly owns 9,009 shares in the company, valued at $545,765.22. The trade was a 4.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 160,924 shares of company stock valued at $14,963,130 in the last ninety days. 20.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have commented on CORT. StockNews.com downgraded Corcept Therapeutics from a "buy" rating to a "hold" rating in a report on Friday, February 28th. Piper Sandler upped their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the stock an "overweight" rating in a research note on Thursday, April 3rd. Canaccord Genuity Group raised their price objective on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, April 1st. Truist Financial upped their target price on shares of Corcept Therapeutics from $76.00 to $150.00 and gave the stock a "buy" rating in a research note on Monday, March 31st. Finally, HC Wainwright raised their price target on shares of Corcept Therapeutics from $115.00 to $150.00 and gave the company a "buy" rating in a research report on Monday, March 31st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $143.25.

Corcept Therapeutics Stock Performance

NASDAQ:CORT traded up $0.89 during mid-day trading on Friday, reaching $68.62. The company's stock had a trading volume of 1,108,760 shares, compared to its average volume of 1,119,457. The firm's fifty day moving average price is $65.72 and its two-hundred day moving average price is $57.69. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The stock has a market cap of $7.24 billion, a P/E ratio of 54.46 and a beta of 0.15. Corcept Therapeutics Incorporated has a 12-month low of $20.84 and a 12-month high of $117.33.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $181.89 million for the quarter, compared to analysts' expectations of $200.12 million. On average, equities analysts forecast that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.